Related Experiment Video
Updated: Jan 25, 2026
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
Ernesto Rossi1, Brigida Anna Maiorano1, Monica Maria Pagliara2
1Medical Oncology, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Abstract:
Conjunctival melanoma is a rare primary ocular tumor. So far, no standard treatment exists for metastatic disease. Similarly to cutaneous melanoma, up to 50% of conjunctival melanomas harbor BRAF mutations. The most common is represented by V600E. Combined therapy with BRAF and MEK inhibitors is approved for BRAF mutant cutaneous metastatic melanomas. Herein, we report a case of a 70-years old patient with a metastatic conjunctival melanoma harboring V600E BRAF mutation successfully treated with dabrafenib and trametinib.
Insights
Metastatic conjunctival melanoma, a rare eye cancer, showed positive results with targeted therapy. A patient with a BRAF V600E mutation responded well to combined BRAF and MEK inhibitors, dabrafenib and trametinib.
Area of Science:
- Ophthalmology
- Oncology
- Medical Genetics
Background:
- Conjunctival melanoma is a rare primary ocular tumor with no established treatment for metastatic disease.
- BRAF mutations, particularly V600E, are found in up to 50% of conjunctival melanomas, similar to cutaneous melanoma.
- Targeted therapies like BRAF and MEK inhibitors are approved for metastatic cutaneous melanoma with BRAF mutations.
Related Concept Videos
01:39Epistasis
01:49Multiple Allele Traits
02:41Protein Complex Assembly
Many viruses self-assemble into a fully functional unit using the infected host cell to...